Delhi HC Allows Zydus to Sell 70% Cheaper Cancer Drug Nivolumab Biosimilar

• Delhi High Court permits Zydus Lifesciences to sell a biosimilar of the cancer drug Nivolumab, 70% cheaper than Bristol Myers Squibb's Opdivo.
• The ruling prioritizes public interest and patient welfare over patent rights, especially for life-saving medicines.
• Zydus's biosimilar, ZRC 3276, aims to drastically reduce treatment costs for aggressive cancers like lung, kidney, and melanoma.
• A division bench overturned an earlier single-judge order that had restrained Zydus, citing the patent's validity until May 2026.
• The decision offers significant relief to cancer patients in India, where high treatment costs often lead to financial hardship.

Why It Matters: Delhi HC allows Zydus to sell a 70% cheaper cancer drug biosimilar, prioritizing patient access over patent rights.